Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Enliven Therapeutics, Inc. (ELVN : NSDQ)

• Company Description    Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO. Number of Employees: 62

• Price / Volume Information    Yesterday's Closing Price: $22.78 Daily Weekly Monthly 20 Day Moving Average: 703,677 shares Shares Outstanding: 49.07 (millions) Market Capitalization: $1,117.80 (millions) Beta: 0.83 52 Week High: $30.03 52 Week Low: $13.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 15.87% 11.53% 12 Week 37.81% 15.92% Year To Date 1.24% -5.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6200 Lookout Road - Boulder,CO 80301 USA ph: 720-647-8519 fax: - ir@enliventherapeutics.com http://www.enliventherapeutics.com

• General Corporate Information    Officers Samuel Kintz - President; Director; and Chief Executive Officer Richard Heyman - Chairman of the Board Benjamin Hohl - Chief Financial Officer Rahul Ballal - Director Jacob Bauer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 29337E102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 49.07 Most Recent Split Date: 2.00 (0.25:1) Beta: 0.83 Market Capitalization: $1,117.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.13 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.88 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -5.56% vs. Previous Quarter: -23.91% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -31.84 12/31/24 - -29.17 ROA 06/30/25 - - 03/31/25 - -30.09 12/31/24 - -27.37 Current Ratio 06/30/25 - - 03/31/25 - 21.07 12/31/24 - 19.99 Quick Ratio 06/30/25 - - 03/31/25 - 21.06 12/31/24 - 19.99 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 5.88 12/31/24 - 6.34 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©